Company intelligence / Profile preview

Grit Biotechnology

Ownership: Private
Employees: ~100
Development stage: Other

Overview

Grit Biotechnology is a clinical-stage cell therapy company specializing in next-generation tumor-infiltrating lymphocyte therapies for advanced solid tumors. Its lead program GT101 is the fastest-developing TIL therapy in China and is currently pivotal/Phase II with plans for BLA submission. The next-gen product GT201 has received IND clearance from both the US FDA and China's CDE. Early data show stable expansion, preliminary efficacy, and good safety profile for these products. The company leverages proprietary technology platforms to enhance T-cell function beyond traditional approaches.

Therapeutic areas: Oncology
Modalities: Tumor-infiltrating lymphocytes (TILs)Genetically engineered TILs
Industry: Biotech

Drug pipeline

12 assets

GT201

11 more assets in the full pipeline.

Partnerships

No major pharma partnerships disclosed; investors include leading VC/private equity groups.

Beyond the preview

Go deeper on Grit Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Grit Biotechnology.